Background The present review is part of the ESCMID Study Group for Infections in
Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and …

Background The present review is part of the ESCMID Study Group for Infections in
Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and …

In the decade since tumor necrosis factor a (TNF-a) antagonists were first approved for
clinical use, they have proven invaluable for the treatment of specific types of chronic …

Background The present review is part of the ESCMID Study Group for Infections in
Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and …

Introduction: The advent, more than two decades ago, of monoclonal antibodies and soluble
receptors targeting tumor necrosis factor (TNF)-α has revolutionized the therapeutic …

Background The present review is part of the European Society of Clinical Microbiology and
Infectious Diseases (ESCMID) Study Group for Infections in Compromised Hosts (ESGICH) …

Introduction: TNF-α inhibitors can be administered either as monotherapy or in combination
with other anti-inflammatory drugs or DMARDs in the treatment of chronic immune-mediated …

Background The present review is part of the European Society of Clinical Microbiology and
Infectious Diseases (ESCMID) Study Group for Infections in Compromised Hosts (ESGICH) …

Introduction: TNF-α is a pro-inflammatory cytokine known to a have a key role in the
pathogenesis of chronic immune-mediated diseases. TNF-α inhibitors can be administered …

Objectives An increased risk of tuberculosis (TB) has been reported in patients treated with
TNF-α antagonists, an issue that has been highlighted in a WHO black box warning. This …